medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number S2

Next >>

Ann Hepatol 2011; 10 (S2)

The burden of hepatic encephalopathy in Latin America

Dávalos MM, Bustios SC

Language: English
References: 32
Page: 31-35
PDF size: 984.48 Kb.


ABSTRACT

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome characterized by changes in cognitive function, behavior, and personality, as well as by transient neurological symptoms and electroencephalographic changes, which occur in the context of acute or chronic liver failure. Cirrhosis is the main disease associated to HE, and it is known that its incidence is increasing worldwide. As a cause of mortality, cirrhosis is ranked 14 worldwide, but 10 in developed countries. It has been demonstrated that the incidence of liver disease is increasing, in part because of the ascending prevalence of NAFLD, HCV, HCC, as well of alcohol consumption. The real incidence of cirrhosis in Latin America is unknown, although in some Latin American countries that provided national data, cirrhosis death rates were between 5 and 17/100,000 for men and 3 and 5/100,000 for women. Disability, quality of life, and social aspects should be considered when assessing the impact of a disease. In this context, preliminary estimates of the global burden of disease attributable to chronic liver disease seem to be substantial. Hepatic encephalopathy, a main complication of liver failure, occurs in 30-45% of patients as overt encephalopathy, but when subclinical or minimal hepatic encephalopathy (MHE) is considered, estimates of the incidence of encephalopathy vary from 20 to 60%. In USA, the 2009 NIH Report on the Costs of Digestive Diseases stated that liver disease was the second most costly disease in direct and indirect costs (13.1 billion dollars). Although the economic cost of HE has not been assessed, it is obvious that the economic impact of HE on daily activities of living is extremely high, as the costs of diminished work performance and lost wages are substantial.


REFERENCES

  1. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.

  2. Blei AT. Diagnosis and treatment of hepatic encephalopathy. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 959-74.

  3. Vom Dahl S, Kircheis G, Haussinger D. Hepatic encephalopathy as a complication of liver disease. World J Gastroenterol 2001; 7(2): 152-6.

  4. Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2006; 25(Suppl. 1): 11-6.

  5. Monteiro MG. Alcohol y Salud Pública en las Américas. Un caso para la acción. Biblioteca Sede OPS-Catalogación en la fuente. Washington, D.C: OPS, ©2007.

  6. WHO Global Infobase: Data for saving lives. Available from: https://apps.who.int/infobase/ [Accessed: November 4th, 2010].

  7. Lopez AD, Mathers CO, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006; 367(9524): 1747-57.

  8. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of Liver Disease in the United States: Summary of a Workshop. Hepatology 2002; 36: 227-40.

  9. El-Serag HB, Andrew CM, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-5.

  10. Murphy S. Deaths: final data for 1998. National vital statistics; reports. Hyattsville, MD: National Center for Health Statistics, 2000, Vol. 48.

  11. Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. Hepatology 2004; 39: 476-83.

  12. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-S9.

  13. Gish RG, Gadano AC. Chronic Hepatitis B: Current Epidemiology in the Americas and Implications for Management. J Viral Hepat 2006; 13(12): 787-98.

  14. Dávalos M. Epidemiología de la infección por Virus C en Perú y Latinoamérica. Rev Gastroenterol Perú 2010; 25: 347-54.

  15. Lavanchy D. The global burden of Hepatitis C. Liver Int 2009; 29: 74-81.

  16. La Vecchia C, Levi F, Lucchini F, Franceschi S, Negri E. Worldwide patterns and trends in mortality from liver cirrhosis, 1955 to 1990. Ann Epidemiol 1994; 4: 480-6.

  17. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: An update to 2002. J Hepatology 2007; 46: 827-39.

  18. Mendez-Sanchez N, García-Villegas E, Merino-Zeferino B, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol 2010; 9: 428-38.

  19. Everhart JE. Liver Disease. Chapter 21th. In: Everhart JE (ed.). The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2008; NIH Publication No. 09-6443 [p. 111-4].

  20. Mathers C, Boerma T, Ma Fat D; World Health Organization staff. The global burden of disease: 2004 update. WHO Library Cataloguing-in-Publication Data.

  21. Poordad FF. The Burden of Hepatic Encephalopathy. Aliment Pharmacol Ther 2006; 25(Suppl. 1): 3-9.

  22. Anonymous. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. Available from: http://hcupnet.ahrq.gov/ [Accessed 15 october 2006].

  23. NIH Report of the American Gastroenterological Association. Available from: http://www.gastro.org/news/articles/ 2009/02/10/nih-report-finds-costs-of-digestive-diseaseshas- grown-to-more-than-141-billion-a-year [Accessed in November 7th, 2010]. 23. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-59.

  24. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531-5.

  25. Yu-Yuan Li, Yu-Qiang Nie, Wei-Hong Sha, Zheng Zeng, Fu- Ying Yang, et al. Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China. World J Gastroenterol 2004; 10(16): 2397-401.

  26. Rikkers L, Jenko P, Rudman D, et al. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology 1978; 75: 462-9.

  27. Groeneweg M, Quero J, De Bruijn I, et al. Subclinical Hepatic Encephalopathy Daily Functioning. Hepatology 1998; 28: 45-50.

  28. Hartmann IJC, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000: 95: 2029-34.

  29. Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999; 29: 1662-7.

  30. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with Motor vehicle crashes: the reality beyond the Driving test. Hepatology 2009; 50(4): 1175-83.

  31. Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14: 3609-15.

  32. Dhiman RK, Saraswat VA, Sharma BK, et al. Minimal hepatic encephalopathy: Consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol and Hepatol 2010; 25: 1029-41.




2020     |     www.medigraphic.com